BACKGROUND: Endothelial colony-forming cells (ECFC) are endowed with vascular regenerative ability in vivo and in vitro. In this study we compared the genotypic profile and the immunogenic potential of adult and cord blood ECFC, in order to explore the feasibility of using them as a cell therapy product. MATERIALS AND METHODS: ECFC were obtained from cord blood samples not suitable for haematopoietic stem cell transplantation and from adult healthy blood donors after informed consent. Genotypes were analysed by commercially available microarray assays and results were confirmed by real-time polymerase chain reaction analysis. HLA antigen expression was evaluated by flow-cytometry. Immunogenic capacity was investigated by evaluating the activation of allogeneic lymphocytes and monocytes in co-cultures with ECFC. RESULTS: Microarray assays revealed that the genetic profile of cord blood and adult ECFC differed in about 20% of examined genes. We found that cord blood ECFC were characterised by lower pro-inflammatory and pro-thrombotic gene expression as compared to adult ECFC. Furthermore, whereas cord blood and adult ECFCs expressed similar amount of HLA molecules both at baseline and after incubation with γ-interferon, cord blood ECFC elicited a weaker expression of pro-inflammatory cytokine genes. Finally, we observed no differences in the amount of HLA antigens expressed among cord blood ECFC, adult ECFC and mesenchymal cells. CONCLUSIONS: Our observations suggest that cord blood ECFC have a lower pro-inflammatory and pro-thrombotic profile than adult ECFC. These preliminary data offer level-headed evidence to use cord blood ECFC as a cell therapy product in vascular diseases.
BACKGROUND: Endothelial colony-forming cells (ECFC) are endowed with vascular regenerative ability in vivo and in vitro. In this study we compared the genotypic profile and the immunogenic potential of adult and cord blood ECFC, in order to explore the feasibility of using them as a cell therapy product. MATERIALS AND METHODS: ECFC were obtained from cord blood samples not suitable for haematopoietic stem cell transplantation and from adult healthy blood donors after informed consent. Genotypes were analysed by commercially available microarray assays and results were confirmed by real-time polymerase chain reaction analysis. HLA antigen expression was evaluated by flow-cytometry. Immunogenic capacity was investigated by evaluating the activation of allogeneic lymphocytes and monocytes in co-cultures with ECFC. RESULTS: Microarray assays revealed that the genetic profile of cord blood and adult ECFC differed in about 20% of examined genes. We found that cord blood ECFC were characterised by lower pro-inflammatory and pro-thrombotic gene expression as compared to adult ECFC. Furthermore, whereas cord blood and adult ECFCs expressed similar amount of HLA molecules both at baseline and after incubation with γ-interferon, cord blood ECFC elicited a weaker expression of pro-inflammatory cytokine genes. Finally, we observed no differences in the amount of HLA antigens expressed among cord blood ECFC, adult ECFC and mesenchymal cells. CONCLUSIONS: Our observations suggest that cord blood ECFC have a lower pro-inflammatory and pro-thrombotic profile than adult ECFC. These preliminary data offer level-headed evidence to use cord blood ECFC as a cell therapy product in vascular diseases.
Authors: David A Ingram; Laura E Mead; Hiromi Tanaka; Virginia Meade; Amy Fenoglio; Kelly Mortell; Karen Pollok; Michael J Ferkowicz; David Gilley; Mervin C Yoder Journal: Blood Date: 2004-06-29 Impact factor: 22.113
Authors: Mervin C Yoder; Laura E Mead; Daniel Prater; Theresa R Krier; Karim N Mroueh; Fang Li; Rachel Krasich; Constance J Temm; Josef T Prchal; David A Ingram Journal: Blood Date: 2006-10-19 Impact factor: 22.113
Authors: Vasileios Karantalis; Wayne Balkan; Ivonne H Schulman; Konstantinos E Hatzistergos; Joshua M Hare Journal: Am J Physiol Heart Circ Physiol Date: 2012-05-25 Impact factor: 4.733
Authors: Luciana Teofili; Maurizio Martini; Maria Grazia Iachininoto; Sara Capodimonti; Eugenia Rosa Nuzzolo; Lorenza Torti; Tonia Cenci; Luigi Maria Larocca; Giuseppe Leone Journal: Blood Date: 2011-01-06 Impact factor: 22.113
Authors: Luciana Teofili; Maria G Iachininoto; Sara Capodimonti; Claudio Ucciferri; Eugenia R Nuzzolo; Maurizio Martini; Lorenza Torti; Katia Falasca; Jacopo Vecchiet; Giuseppe Leone; Luigi M Larocca Journal: AIDS Date: 2010-10-23 Impact factor: 4.177
Authors: Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén Journal: Lancet Date: 2008-05-10 Impact factor: 79.321
Authors: Anton G Kutikhin; Alexey E Tupikin; Vera G Matveeva; Daria K Shishkova; Larisa V Antonova; Marsel R Kabilov; Elena A Velikanova Journal: Cells Date: 2020-04-03 Impact factor: 6.600